P1/2, N=38, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.

16 days ago

Trial termination

TP53 (Tumor protein P53)

TP53 wild-type

Venclexta (venetoclax) • cytarabine • cyclophosphamide • topotecan • idasanutlin (RG7388) • fludarabine IV

18d

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=404, Recruiting, Biotheus Inc. | Not yet recruiting --> Recruiting

18 days ago

Enrollment open

paclitaxel • topotecan • BNT327

21d

Synergistic Therapy of Metastatic Breast Cancers by Biomimetic Chemotherapeutic Drug-Gene Nanoparticles. (PubMed, ACS Appl Mater Interfaces)

First, topotecan hydrochloride (TPT) and vascular endothelial growth factor antisense oligonucleotide (ASOVEGF) were coself-assembled in water through electrostatic interaction to produce chemotherapeutic drug-gene nanoparticles (TPT-ASOVEGF NPs)...In MBC mouse models, the in vivo inhibition rate of TPT-ASOVEGF@MM NPs for lung metastasis was 89.5%, with minor toxic side effects and the least number of metastatic nodules in the lungs. In summary, TPT-ASOVEGF@MM NPs would be a promising biomimetic nanodrug for chemo-gene combination therapy of MBC with high efficacy and safety in clinics.

21 days ago

Journal • Metastases

HIF1A (Hypoxia inducible factor 1, alpha subunit)

HIF1A expression • VEGFA expression

topotecan

23d

STEP-RB: Topotecan Episcleral Plaque for Treatment of Retinoblastoma (clinicaltrials.gov)

P1, N=26, Completed, The Hospital for Sick Children | Recruiting --> Completed | Trial completion date: Oct 2030 --> Oct 2024 | Trial primary completion date: Oct 2025 --> Oct 2024

23 days ago

Trial completion • Trial completion date • Trial primary completion date

topotecan • topotecan episcleral

23d

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. (PubMed, J Clin Oncol)

Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.

23 days ago

P3 data • Journal • BRCA Biomarker • PARP Biomarker

BRCA (Breast cancer early onset)

BRCA mutation

Lynparza (olaparib) • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan

24d

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC (clinicaltrials.gov)

P3, N=180, Recruiting, Luye Pharma Group Ltd. | Not yet recruiting --> Recruiting

24 days ago

Enrollment open • Combination therapy

irinotecan • topotecan • Zepzelca (lurbinectedin)

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (clinicaltrials.gov)

P3, N=110, Not yet recruiting, Children's Oncology Group | Initiation date: Dec 2024 --> Mar 2025

1 month ago

Trial initiation date • Surgery

TP53 (Tumor protein P53) • DICER1 (Dicer 1 Ribonuclease III)

doxorubicin hydrochloride • cyclophosphamide • ifosfamide • vincristine • daunorubicin • topotecan • dactinomycin • dexrazoxane

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)

P2/3, N=260, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025

1 month ago

Trial completion date

BRAF (B-raf proto-oncogene)

Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)

A Study of N9 Chemotherapy in Children With Neuroblastoma (clinicaltrials.gov)

P1, N=26, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

MYCN amplification

carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna

A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=240, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2026 --> Jul 2026

1 month ago

Enrollment open • Trial primary completion date • Metastases

topotecan • GSK5764227

The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy (clinicaltrials.gov)

P1, N=50, Not yet recruiting, Massachusetts Eye and Ear Infirmary | Initiation date: Jul 2024 --> Jan 2025

1 month ago

Trial initiation date

topotecan

2ms

CA116-001: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)

P2, N=90, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

FOLR1 ( Folate receptor alpha )

paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)

2ms

MIRASOL: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (clinicaltrials.gov)

P3, N=453, Completed, ImmunoGen, Inc. | Active, not recruiting --> Completed

2 months ago

Trial completion • Metastases

FOLR1 ( Folate receptor alpha )

FOLR1 expression

paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan

2ms

Alternative lengthening of telomere-based immortalization renders H3G34R -mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens. (PubMed, Neuro Oncol)

Our preclinical and clinical data strongly support the further development of PARPis together with DNA damage stress-inducing treatment regimens for DHG-H3G34R_ATRX.

2 months ago

Journal • PARP Biomarker

ATRX (ATRX Chromatin Remodeler) • RAD51 (RAD51 Homolog A)

Talzenna (talazoparib) • Zejula (niraparib) • irinotecan • topotecan

2ms

Multi-omics analysis revealed significant metabolic changes in brain cancer cells treated with paclitaxel and/or topotecan. (PubMed, Heliyon)

Overall, this study underscores the effectiveness of multi-omics approaches in revealing the molecular mechanisms driving chemotherapy responses in cancer cells. Additionally, this work generates a comprehensive list of molecular alterations that can serve as a foundation for further investigations and inform personalized healthcare strategies to enhance patient outcomes.

2 months ago

Journal

HIF1A (Hypoxia inducible factor 1, alpha subunit) • RACK1 (Receptor For Activated C Kinase 1) • RPA3 (Replication Protein A3)

paclitaxel • topotecan

2ms

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (ChiCTR2400090371)

P3, N=394, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

2 months ago

New P3 trial

topotecan • pegylated irinotecan (SSS22)

2ms

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (ChiCTR2400091077)

P3, N=404, Recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

2 months ago

New P3 trial • Combination therapy

paclitaxel • topotecan • BNT327

2ms

Retinoblastoma Phase II Expanded Access Clinical Trial (clinicaltrials.gov)

P2, N=30, Not yet recruiting, Targeted Therapy Technologies, LLC

2 months ago

New P2 trial

topotecan • topotecan episcleral

2ms

Rapid Administration Pilot for Infusing Dinutuximab (clinicaltrials.gov)

P4, N=11, Suspended, Children's Hospital Los Angeles | Trial completion date: Aug 2024 --> Jun 2025 | Recruiting --> Suspended | Trial primary completion date: Aug 2024 --> Jun 2025

2 months ago

Trial completion date • Trial suspension • Trial primary completion date

temozolomide • cyclophosphamide • irinotecan • topotecan • Unituxin (dinutuximab)

2ms

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies. (PubMed, Cancer Lett)

In the tumor-bearing mouse model, mobocertinib boosted the antitumor effect of paclitaxel and topotecan, resulting in tumor regression. In summary, our study uncovers a novel potential for repurposing mobocertinib as a dual inhibitor of ABCB1 and ABCG2, and suggests the combination of mobocertinib with substrate drugs as a strategy to counteract MDR.

2 months ago

Preclinical • Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)

EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • ABCB1 overexpression • ABCG2 expression

paclitaxel • topotecan • Exkivity (mobocertinib)

2ms

REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)

P2/3, N=650, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)

3ms

MEF2C is a Potential Prognostic Biomarker and is Correlated with Immune Infiltrates in Lung Adenocarcinoma. (PubMed, Curr Med Chem)

The results imply that MEF2C could be a valuable indicator for predicting outcomes and a possible target for immunotherapy for LUAD patients.

3 months ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • MEF2C (Myocyte Enhancer Factor 2C)

Tasigna (nilotinib) • irinotecan • topotecan • Farydak (panobinostat)

3ms

P3, N=110, Not yet recruiting, Children's Oncology Group

3 months ago

New P3 trial • Surgery

TP53 (Tumor protein P53) • DICER1 (Dicer 1 Ribonuclease III)

doxorubicin hydrochloride • cyclophosphamide • ifosfamide • vincristine • daunorubicin • topotecan • dactinomycin • dexrazoxane

3ms

NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)

P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025

3 months ago

Trial completion date

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)

MYCN amplification • IL6 expression

cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane

3ms

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

topotecan • GSK5764227

3ms

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)

P3, N=530, Not yet recruiting, Genmab

3 months ago

New P3 trial

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • rinatabart sesutecan (PRO1184)

3ms

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. (PubMed, Sci Adv)

This study shows that targeting ATR up-regulates major histocompatibility class I expression in preclinical models and SCLC clinical samples collected from a first-in-class clinical trial of ATR inhibitor, berzosertib, with topotecan in patients with relapsed SCLC. Targeting ATR represents a transformative vulnerability of SCLC and is a complementary strategy to induce STING-interferon signaling-mediated immunogenicity in SCLC.

3 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

STING (stimulator of interferon response cGAMP interactor 1)

berzosertib (M6620) • topotecan

3ms

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=404, Not yet recruiting, Biotheus Inc.

3 months ago

New P3 trial • Combination therapy

paclitaxel • topotecan • BNT327

3ms

A Phase III Study to Evaluate the Efficacy and Safety of YL201 in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=438, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.

3 months ago

New P3 trial

topotecan • YL201

3ms

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov)

P1/2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Aug 2025

3 months ago

Trial completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

veliparib (ABT-888) • topotecan

4ms

DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov)

P1, N=54, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Apr 2026

4 months ago

Trial completion date • Combination therapy

PD-L1 (Programmed death ligand 1)

topotecan • obrixtamig (BI 764532)

4ms

NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov)

P1, N=221, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete

4 months ago

Trial completion date • Trial termination • Trial primary completion date • Combination therapy • IO biomarker • Metastases

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)

4ms

A Prospective, Single-Arm, Exploratory Clinical Study of Anti-PD-1 Monoclonal Antibody Combined with Topotecan Capsules for Consolidation of Limited Stage Small Cell Lung Cancer That Has Not Progressed After Concurrent or Sequential Chemoradiotherapy (ChiCTR2400088636)

P=N/A, N=46, Recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital

4 months ago

New trial

Loqtorzi (toripalimab-tpzi) • topotecan

4ms

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (clinicaltrials.gov)

P2, N=128, Active, not recruiting, Pfizer | Phase classification: P1/2 --> P2 | Trial completion date: Feb 2025 --> Oct 2025

4 months ago

Phase classification • Trial completion date • Combination therapy

EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein)

Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan

4ms

A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=260, Not yet recruiting, GlaxoSmithKline | N=100 --> 260

4 months ago

Enrollment change • Metastases

topotecan • GSK5764227

4ms

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=394, Not yet recruiting, JenKem Technology Co., Ltd.

4 months ago

New P3 trial

topotecan • pegylated irinotecan (SSS22)

4ms

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov)

P2/3, N=600, Recruiting, Sutro Biopharma, Inc. | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Sep 2025 --> Aug 2027

4 months ago

Trial completion date • Trial primary completion date

FOLR1 ( Folate receptor alpha )

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)

4ms

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (clinicaltrials.gov)

P1, N=71, Active, not recruiting, Eli Lilly and Company | Trial completion date: Aug 2024 --> Aug 2025

4 months ago

Trial completion date

cyclophosphamide • topotecan • LY3295668

5ms

BL-B01D1-304: A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=652, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

5 months ago

Enrollment open

topotecan • izalontamab brengitecan (BL-B01D1)

5ms

Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. (PubMed, MedComm (2020))

Finally, we found that both pharmacological and genetic silence of USP22 sensitize RSL3-induced ferroptosis through suppressing the PI3K/Akt/mTOR pathway and its downstream SCD, and ferroptosis inhibitor could partly rescued the decreased lung metastasis by topotecan in vivo. Overall, our findings reveal a prometastatic role of USP22 and identify topotecan as a potent USP22-targeting drug to limit melanoma metastasis.

5 months ago

Journal

PTEN (Phosphatase and tensin homolog) • USP22 (Ubiquitin Specific Peptidase 22)

topotecan • RSL3